Datos personales

Mi foto
Fundador y managing partner de Innovative Bioconsulting, una consultora dirigida a empresas biotecnológicas. Profesor de Gestión Empresaria en el Máster de Biotecnología de la Escuela de Negocios Aliter, Madrid, España. Tutor de Emprendedores de IE Business School. Anteriormente ha desarrollado su carrera profesional en el sector biofarmacéutico, con experiencia multinacional y creación de dos empresas. Master en Biotecnología y MBA

martes, 28 de julio de 2015

M&A trends from january to june 2015

Yesterday I received the interesting Linda Pullan's newsletter (I recommend you to subscribe at her website)  with some interesting and meaningful data on mergers and acquisitions in the biotech industry. I think it worth sharing as the data shows a significant activity for the first half of the year.

The M&A activity in the 1st half of 2015 is not as frenzied as last years, but is active.



A decade in deal making 

Year announced Deal Value ($bn) Deal Count 

2015 H1 95 121 

2014 217 199 

2013 80 199 

2012 43 198 

2011 56 203 

2010 109 198 

2009 152 171 

2008 109 188 

2007 71 171 

2006 101 153 

NB: Data include mega-mergers 
EvaluatePharma
 

M&A Trends:  
1.  Rare diseases.  Among the leaders in 2Q 2015 was Alexion in the big trend of rare disease companies needing to buy or be bought.
2.  Specialty and generics.   Actavis (now called Allergan) has been the biggest spender in M&A for the last few years and just gobbled up Kythera, the So Cal derm company led by ex-Amgen folks.  Reflecting the roll-up of specialty and generic firms, Valeant is 2nd most active over the last few years.  

3.  Some big pharma but not others are M&A driven.


The industry's big spenders - three-year M&A bill   
Big pharma 
Company   3yr spend ($bn)   3yr deal count   M&A ranking   
Pfizer  19.3 
Novartis  17.8 10 
AbbVie  17.6 
Merck & Co  13.8 
Roche  11.9 10 
Total 10 big pharma 93.8 65 
Other big drug makers (market cap ≥$20bn)  
Company   3yr spend ($bn)   3yr deal count   M&A ranking   
Allergan  112.3 10 
Valeant Pharmaceuticals  24.6 
Bayer  17.7 
Perrigo Company  14.7 
Endo International  14.6 
Total 88 non-big pharma 299.5 240 
EvaluatePharma

No hay comentarios:

Publicar un comentario en la entrada